| |
| Names | |
|---|---|
| IUPAC name N--6-methoxy-3,5-dioxo-1,2,4-triazin-2-yl]-2-fluorophenyl]acetamide | |
| Identifiers | |
| CAS Number | |
| 3D model (JSmol) | |
| PubChem CID | |
InChI
| |
SMILES
| |
| Properties | |
| Chemical formula | C19H15ClF2N4O4 |
| Molar mass | 436.80 g·mol |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Infobox references | |
ADX-71441 is a GABAB receptor positive allosteric modulator currently being investigated as a potential treatment for anxiety, epilepsy, pain and other conditions.
Therapeutic potential
Addiction
ADX-71441 has been shown to reduce alcohol consumption. This result was observed in both alcohol dependent and non-dependent animals.
There were also trials about nicotine addiction, which showed positive results: ADX-71441 was able to decrease some withdrawal symptoms of nicotine withdrawal.
Anxiety
This compound has also been shown to reduce anxiety in people with PTSD.
Pain
Experiments have shown that this compound was able to decrease hypersensitivity to pain in mice, Guinea pigs and rats.
Tolerance
ADX-71441 has been shown to have less tolerance and side effects than direct GABAB agonists, such as baclofen.
References
- "Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence". Addex therapeutics. Retrieved 2024-02-03.
- ^ Augier E, Dulman RS, Damadzic R, Pilling A, Hamilton JP, Heilig M (August 2017). "The GABAB Positive Allosteric Modulator ADX71441 Attenuates Alcohol Self-Administration and Relapse to Alcohol Seeking in Rats". Neuropsychopharmacology. 42 (9): 1789–1799. doi:10.1038/npp.2017.53. PMC 5520784. PMID 28294133.
- Colombo G (March 2024). "Positive allosteric modulators of the GABAB receptor: a new class of ligands with therapeutic potential for alcohol use disorder". Alcohol and Alcoholism. 59 (3). Oxford, Oxfordshire. doi:10.1093/alcalc/agae018. PMID 38566580.
- "Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction". Addex therapeutics. Retrieved 2024-02-03.
- ^ Kalinichev M, Girard F, Haddouk H, Rouillier M, Riguet E, Royer-Urios I, et al. (March 2017). "The drug candidate, ADX71441, is a novel, potent and selective positive allosteric modulator of the GABAB receptor with a potential for treatment of anxiety, pain and spasticity". Neuropharmacology. 114: 34–47. doi:10.1016/j.neuropharm.2016.11.016. PMID 27889489. S2CID 36606154.